Your session is about to expire
← Back to Search
Pembrolizumab for Bladder Cancer
Study Summary
This trial is testing pembrolizumab as a treatment for bladder cancer patients undergoing surgery. It will look at side effects and how well the immunotherapy works.
- Bladder Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are being recruited for this experiment?
"Unfortunately, this trial is no longer seeking participants. Initially posted on November 1st 2018 and last updated October 20th 2022, interested individuals should explore the 315 active trials involving urinary bladder or 961 Pembrolizumab studies currently recruiting."
What other experiments have been conducted with Pembrolizumab as the focus?
"At present, 961 clinical investigations are underway that focus on Pembrolizumab. Of these studies, 122 have progressed to Phase 3 trials. The majority of the trails for this treatment occur in Houston, Texas, yet there are 35 731 research sites hosting related tests worldwide."
Are there still opportunities for patients to join this experiment?
"This particular clinical trial is now closed to new participants. Initially posted on November 1st 2018 and last updated October 20th 2022, those searching for alternative medical studies can find 315 trials currently recruiting patients with urinary bladder conditions and 961 trials actively enrolling individuals using Pembrolizumab."
How is Pembrolizumab typically utilized in treatment?
"Pembrolizumab is regularly prescribed for cancerous neoplasms but can also be used to treat the progression of disease after chemotherapy, unresectable melanoma, and microsatellite instability high."
Has Pembrolizumab attained regulatory approval from the Food and Drug Administration?
"As this is a Phase 2 trial, meaning there are some data indicating safety but not efficacy, our team at Power assess the risk of Pembrolizumab to be a level 2."
Share this study with friends
Copy Link
Messenger